Track, trace system roll out for drug formulation exports extended again
The Hindu
The Directorate General of Foreign Trade has agreed to yet another plea from drugmakers for more time to implement the Track and Trace system for export of drug formulations.
The Directorate General of Foreign Trade has agreed to yet another plea from drugmakers for more time to implement the Track and Trace system for export of drug formulations.
“The date for implementation of the Track and Trace system for export of drug formulations with respect to maintaining the parent-child relationship in packaging levels and its uploading on Central portal has been extended up to February 1, 2025 for both SSI and non-SSI manufactured drugs,” the DGFT said in a notification recently extending the deadline by one more year.
Conceived as a mechanism to rein in the counterfeit menace and address the challenges associated with product recall, the system has been in the offing for at least nine years with DGFT in August, in the previous extension notification, setting a February 1, 2024 deadline.
The latest extension comes on the heels of a representation from the Pharmaceuticals Export Promotion Council of India to the Commerce Department on the difficulties expressed by its member exporters with regard to implementation of track and trace and requested for extension of timelines. Pharmexcil Director General Ravi Uday Bhaskar told The Hindu the request for more time was made in the light of issues with the software during a pilot project for uploading secondary and tertiary packing data. The glitches have also been taken to the notice of C-DAC, the software developer, he said.
Towards facilitating the roll out, the government has a scheme under which it provides ₹25 lakh grant, for the barcode machinery, to SSI units. The delay in implementation continues even as drug regulators in several countries such as Uzbekistan and Nigeria either have mandated measures or are proposing norms on the lines of the Track and Trace system for those from whom they import.
Rupee hits all-time low at 85.20 against USD due to strong greenback, rising crude oil prices, and weak domestic markets.
Viatris faces U.S. FDA import alert for products from Indore plant, exceptions made for certain shortages.
xAI’s Grok may soon come to an iOS app as the company announced its Series C funding round of $6 billion.
Biocon and Zentiva receive EU approval for Liraglutide, a complex formulation for diabetes and weight management.
Equity markets fluctuate as Sensex and Nifty rise initially, then fall; global markets and oil prices also discussed.
Microsoft has been working on adding internal and third-party AI models to power Microsoft 365 Copilot.
China's dominance in critical minerals poses supply chain vulnerabilities for India, US, and EU nations, requiring strategic diversification efforts.
India's controversial popcorn tax system sparks outrage and criticism, with opposition questioning the complex GST rates.
ICAI President investigates auditing lapses at Byju's, disciplinary committee probing, details undisclosed, part of ongoing investigations.
Sensex and Nifty rebound sharply after steep decline, driven by value buying, bluechip stocks, and global market rally.
AS-IT-IS Nutrition aims for ₹300 crore GMV in 2025 with ATOM range, endorsed by Ravindra Jadeja.